Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of paediatric Eurartesim formulations in infants with uncomplicated falciparum malaria
2013-002255-15Phase 2
- Sponsor
- Leadiant Biosciences
- Start
- Nov 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dihydroartemisinin in Malaria (3 arms), sponsored by Leadiant Biosciences. Primary endpoint: Population and individual pharmacokinetic parameters of piperaquine and dihydroartemisinin.
02
Drugs
dihydroartemisinin
03
Conditions
Malaria
Beyond the preview
Go deeper on 2013-002255-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002255-15.